// App-Quantinova.ai

Filters

Biomarkers











Conference Name






Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























387 Abstracts

Inflammatory activation biomarker profile after marathon run and its impact on cardiovascular stress biomarker release in amateur middle-aged male runners

M. Kosowski - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

ILS-969

B-type natriuretic response and non-restrictive mitral flow are predictors of left ventricular reverse remodeling and influence the outcome of patients with heart failure with reduced ejection fractio

F.L. Dini - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Chromogranin B - emerging biomarker in heart failure

F.M. Heidrich - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Angiotensin II

Combined predictability of valvular calcification, B-type natriuretic peptide and cardiac troponin T for cardiovascular mortality in chronic hemodialysis patients

H. Takahashi - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Brain natriuretic peptide is good predictor for assessing super responders of adaptive servo ventilation therapy in patients with heart failure

A. Umeyama - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Serum proatrial and B-type natriuretic peptide do not increase with higher systolic blood pressure in obese men despite evidence of greater left atrial size and higher left ventricular mass

C.L. Asferg - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Six-segments right ventricular global longitudinal strain predicts survival in patients with pulmonary hypertension receiving specific vasodilator therapy

B.A. Popescu - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Sildenafil citrate

Acute heart failure symptoms and Brain natriuretic peptide levels variation after left atrial appendage occlusion

R.R. Robert - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Prognostic impact of B-type natriuretic peptide after transcatheter aortic valve replacement in patients with severe aortic stenosis

K. Sato - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Improvement of the cardiac hemodynamic performance among dialysis patients with end-stage renal disease by active fluid management modulation

M. Dekleva - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Longer Ischemic Time Is Associated with Late Graft Dysfunction in Pediatric Heart Transplant Recipients.

L. Schroeder - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

A new mutation causing arrhythmogenic right ventricular cardiomyopathy with atypical presentation

A Aimo - Heart Failure Congress (HFC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmogenic right ventricular cardiomyopathy

Technetium (99mTc) sestamibi

Rapidly progressive heart failure symptoms in a patient with amyloid cardiomyopathy caused by rare Glu89Lys TTR mutation

M Gawor - Heart Failure Congress (HFC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

AL Amyloidosis

Tafamidis meglumine

CARDIOPROTECTIVE EFFECTS OF ATORVASTATIN IN B-CELL LYMPHOMA PATIENTS RECEIVING RCHOP REGIMEN, A RANDOMIZED CONTROLLED TRIAL

Atisa Koonarat - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Atorvastatin

Fetal cardiac remodeling associated with preeclampsia and fetal growth restriction

Fatima Crispi - Society for Maternal-Fetal Medicine (SMFM) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Preeclampsia

N/A

The Relation Between Coronary Endothelial Dysfunction and High Platelet Aggregability

Masafumi Takae - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Adenosine-5'-triphosphate

Obesity Paradox on Outcome in Atrial Fibrillation Maintained Even Considering the Prognostic Influence of Biomarkers: Insights From the ARISTOTLE Trial

Roopinder K Sandhu - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Interleukin

Prevalence and Significance of Atrial FDG Uptake in Patients With Cardiac Sarcoidosis

Kenji Yodogawa - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Angiotensin II

B-Type Natriuretic Peptide May Be a Suitable Predictor for Sinus Maintenance After Pulmonary Vein Isolation in Patients With Enlarged Left Atrium

Koji Yasumoto - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Urinary N-terminal Fragment of Titin Distinguishes Muscular Dystrophy From Other Types of Cardiomyopathy

Takatoyo Kiko - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved